Osteoprotegerin Inhibits Aortic Valve Calcification and Preserves Valve Function in Hypercholesterolemic Mice

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Weiss, Robert M ^a   Lund, Donald D ^a   Chu, Yi ^a   Brooks, Robert M ^a   Zimmerman, Kathy A ^a   Accaoui, Ramzi El ^a   Davis, Melissa K ^a   Hajj, Georges P ^a   Zimmerman, M Bridget ^b   Heistad, Donald D ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCALCIN; OSTEOPROTEGERIN; APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE CALCIFICATION; AORTA VALVE DISEASE; ARTICLE; BONE DEVELOPMENT; CALCIFICATION; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; LIPID STORAGE; MALE; MOUSE; NONHUMAN; AGE; ANIMAL; AORTA VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ECHOGRAPHY; GENETICS; INJECTION; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

MUS;

AGE FACTORS; ANIMALS; AORTIC VALVE; AORTIC VALVE STENOSIS; APOLIPOPROTEIN B-100; CALCINOSIS; DISEASE MODELS, ANIMAL; FEMALE; HYPERCHOLESTEROLEMIA; INJECTIONS; MALE; MICE; MICE, TRANSGENIC; OSTEOGENESIS; OSTEOPROTEGERIN; RECEPTORS, LDL;

EID: 84878793167     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065201     Document Type: Article

References (24)

1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, et al. (2006) Burden of valvular heart diseases: A population-based study. Lancet 368: 1005-1011.
2. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, et al. (2005) A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352: 2389-2397.
3. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, et al. (2007) Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49: 554-561.
4. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, et al. (2008) Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359: 1343-1356.
5. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, et al. (2010) Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 121: 306-314.
6. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, et al. (2008) focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 118: e523-661.
7. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD, (1994) Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Circulation 90: 844-853.
8. Shao JS, Cheng SL, Sadhu J, Towler DA, (2010) Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension 55: 579-592.
9. Miller JD, Weiss RM, Heistad DD, (2011) Calcific Aortic Valve Stenosis: Methods, Models, and Mechanisms. Circulation Res 108: 1392-1412.
10. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. 89: 309-319.
11. Tintut Y, Demer LL, (2006) Role of Osteoprotegerin and Its Ligands and Competing Receptors in Atherosclerotic Calcification. J Investig Med 54: 395-401.
12. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, et al. (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268.
13. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, et al. (2008) Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in Ldlr-/- mice. Circulation 117: 411-420.
14. Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD, (2006) Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 114: 2065-2069.
15. Miller JD, Weiss RM, Serrano KM, Brooks RM, Berry CJ, et al. (2009) Lowering plasma cholesterol halts progression of aortic valve disease in mice. Circulation 119: 2693-2701.
16. Miller JD, Weiss RM, Serrano KM, Brooks RM, Berry CJ, et al. (2010) Evidence for active regulation of pro-osteogenic signaling in advanced aortic valve disease. Arterioscler Thromb Vasc Biol 2010 30: 2482-2486.
17. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, et al. (2005) NFAT and Osterix cooperatively regulate bone formation. Nat Med 11: 880-885.
18. Stein GS, Lian JB, Stein JL, Van Wijnen AJ, Montecino M, (1996) Transcriptional control of osteoblast growth and differentiation. Physiol Rev 76: 593-629.
19. Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarikoç A, et al. (2004) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36: 57-66.
20. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, et al. (2009) RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circulation Res 104: 1041-1048.
21. Wallby L, Janerot-Sjöberg B, Steffensen T, M Broqvist M, (2002) T-lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 88: 348-351.
22. Otto CM, (2008) Calcific aortic stenosis-time to look more closely at the valve. N Engl J Med 359: 1395-1398.
23. Hjortnaes J, Butcher J, Figueiredo JL, Riccio M, Kohler RH, et al. (2010) Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodeling: a role for inflammation. Eur Heart J 31: 1975-1984.
24. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, et al. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756-765.